AN EXTENSIVE PRODUCT PIPELINE
In 2019, the FDA approved HBT’s Abbreviated New Drug Application to market and sell its Fulvestrant product, a generic equivalent to Faslodex®, for the treatment of certain types of breast cancer. In early 2020, through its marketing partner, HBT Labs launched commercial sales of Fulvestrant in the US.

In 2018, HBT Labs filed a New Drug Application with the FDA under Section 505(b)(2) for approval to market and sell HBT’s Paclitaxel product for the treatment of certain types of breast cancer.



FULVESTRANT INJECTION
Container Type Prefilled Syringe
Strength 250 mg per 5 mL
Concentration 50 mg per mL
Fill Volume 5 mL
Syringe Size 5 mL
Our mission is to develop and deliver cost-effective, high-quality therapeutics for patients in critical need.